Bristol-Myers Squibb Company announced its financial results for the first quarter of 2026 through a press release and a supplemental presentation. The filing provides details regarding the company's financial performance and various operating initiatives for the period.

Bristol-Myers Squibb Company announced its financial results for the fourth quarter and full year of 2025 via a press release and investor presentation. The filing also includes details regarding the company's financial and operating initiatives.

Bristol-Myers Squibb announced the early settlement and participation results of its previously announced cash tender offers to repurchase various company notes. The company issued press releases on November 17 and 18, 2025, detailing the accepted amounts and pricing terms for these debt repurchases.

Bristol-Myers Squibb completed a €5 billion public offering of five series of notes through its subsidiary, BMS Ireland Capital Funding, with maturities ranging from 2030 to 2055. The company intends to use the proceeds, along with approximately $3.0 billion in cash on hand, to fund a tender offer for its outstanding notes and for general corporate purposes.